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MicroRNAs, the non-coding single-stranded RNA of 19–25 nucleotides are emerging as robust players of gene regulation.
Plethora of evidences support that the ability of microRNAs to regulate several genes of a pathway or even multiple cross
talking pathways have significant impact on a complex regulatory network and ultimately the physiological processes and
diseases. Brain being a complex organ with several cell types, expresses more distinct miRNAs than any other tissues. This
review aims to discuss about the microRNAs in brain development, function and their dysfunction in brain tumors. We
also provide a comprehensive summary of targets of brain specific and brain enriched miRNAs that contribute to the
diversity and plasticity of the brain. In particular, we uncover recent findings on miRNA-128, a brain-enriched microRNA
that is induced during neuronal differentiation and whose aberrant expression has been reported in several cancers. This
review describes the wide spectrum of targets of miRNA-128 that have been identified till date with potential roles in
apoptosis, angiogenesis, proliferation, cholesterol metabolism, self renewal, invasion and cancer progression and how this
knowledge might be exploited for the development of future miRNA-128 based therapies for the treatment of cancer as
well as metabolic diseases.
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MicroRNAs are small non-coding RNAs of 19–25 nucleo-
tides in length and are known to regulate several protein-
coding genes both in plants and animals. The first miRNA,
lin-4 that controlled developmental timing in Caenorhabdi-
tis elegans was identified by two different groups in 1993
[1,2]. Later, let-7 miRNAs were found to control the timing
of fate specification of neuronal and hypodermal cells dur-
ing larval development [3-5]. Subsequently, numerous miR-
NAs have been implicated in a variety of cellular processes
including differentiation, apoptosis, cell proliferation, em-
bryonic development, stem cell renewal, stress response
and metabolism [6-11]. Their profound impact on the regu-
lation of numerous cellular processes clearly suggests that
any aberration in miRNA biogenesis pathway or its regula-
tion contributes to several human diseases such as cancer
[12-14], cardiovascular diseases [15], schizophrenia [16],* Correspondence: nsaini@igib.in
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article, unless otherwise stated.psoriasis [17], diabetes [18], chronic hepatitis [19], AIDS
[20], and obesity [21].
MicroRNAs (miRNAs) interfere with target gene ex-
pression by binding to the 3′ UTRs of their target mRNAs
and act primarily at the level of translation. Complete
complementarity between miRNA and 3′UTR of its target
leads to the degradation of mRNA targets as shown in
plants whereas partial complementarity leads to inhibition
of translation as seen in mammals [22-24]. Literature re-
veals that a single miRNA can target several mRNAs to-
gether, and a single mRNA can be targeted by different
miRNAs in a concerted manner. Large number of micro-
RNAs and the capacity of each miRNA to target several
transcripts suggest a complex regulatory network to fine
tune the gene expression and a mechanism by which they
are thought to regulate various processes during health
and disease [25].
The advancement of high-throughput sequencing tech-
niques has led to the rapid growth in the number of an-
notated miRNA. The most recent miRBase Sequence
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expressing 30424 mature miRNA products in 193 species
[26]. The sequences of most miRNAs are conserved across
large evolutionary distances, suggesting a conserved role
in regulation of various physiological processes [27].
The diversity and gene-regulatory capacity of miRNAs
is particularly valuable in the brain, where persistent flow
of information and functional specialization of neurons re-
quires constant neuronal adaptation to environmental cues
[28]. The brain expresses more distinct and largest number
of miRNAs than any other tissue in vertebrates as it has
wide variety of cell types, neuronal and nonneuronal (for
e.g. astrocytes) [29]. In this review, we summarize present
knowledge on the microRNA expression and functions
in the brain and their potential involvement in relation
to brain tumors. Herein, we also give an overview of the
functions and targets of brain-enriched and brain-specific
miRNAs before delving into specific example of miRNA-
128, the most abundant brain-enriched miRNA. We believe
that the understanding of the impact of microRNA-128 on
regulation of proliferation, apoptosis and metabolic pro-
cesses is still at its dawn and needs further research for the
development of future miRNA-based therapies for the
treatment of metabolic diseases and cancer.
MiRNA biogenesis and mechanism of action
Approximately, 50% of the mammalian miRNAs have
found their location in introns or exons of protein-coding
genes or introns of long non-coding RNAs [30,31]. Their
expression is either derived by independent transcriptional
units or by protein-coding gene transcriptional units [32].
As shown in Figure 1, miRNAs are transcribed from gen-
omic DNA by RNA polymerase II or III into long, primary
transcripts (pri-miRNAs) just like other protein coding
genes. These pri-miRNAs are several kilobases in length
and usually possess a 5′ CAP and a 3′ poly (A) tail. These
pri-miRNAs are processed by a microprocessor complex
which consists of a ribonuclease III (RNase III) named
Drosha, a RNA-binding protein DiGeorge syndrome crit-
ical region 8 (DGCR8/Pasha) and a variety of co-factors
[DEAD box helicases p68 and p72 and the heterogeneous
nuclear ribonucleoproteins (hnRNPs)] which are thought
to promote the specificity and/or activity of Drosha cleav-
age [32-35]. Drosha processing occurs co-transcriptionally
in most mammalian miRNAs i.e. before splicing of host
RNA (canonical pathway). However, Drosha pathway can
be evaded by miRtrons (a subset of intronic miRNAs) and
are made by splicing and debranching of short hairpin in-
trons [36,37]. The product of Drosha cleavage is a 70–100
nucleotide hairpin-shaped precursor referred to as pre-
miRNA. These pre-miRNAs are exported to the cytoplasm
by Ran-GTP and Exportin-5 dependent mechanisms [38].
In cytoplasm, these pre-miRNAs are excised by the RNase
III enzyme Dicer into a double-stranded RNA of ~22nucleotides in length, referred to as the miRNA:miRNA*
duplex or by Ago2, an Argonaute protein that is part of
the RISC complex and aligns the miRNA and messenger
RNA [39,40]. The criteria for binding and cleavage by Ago2
after the 30th nucleotide are short stem and spanning of the
loop by miRNA sequence. The duplex produced by either
Dicer or Ago2 is loaded onto an Argonaute protein where
one strand, i.e. guide strand, complementary to the target
mRNA, is selected and subsequently forms the miRNA ef-
fector as part of a miRISC (miRNA-induced silencing com-
plex), while the remaining strand (the “passenger strand”) is
released and degraded [41]. Similar to Drosha and Dicer
assisting proteins, the formation of the miRISC and the
execution of its activity involve many additional factors
[42]. The two key factors involved in the assembly and
function of miRISCs are Argonaute (AGO) proteins, which
directly interact with miRNAs, and glycine-tryptophan pro-
tein of 182 kDa (GW182), which act as downstream effec-
tors in the repression. miRNA then guides the miRISC to
recognize the partially complementary binding sites located
in the 3′UTR of their target mRNAs.
The perfect binding between seed region (5′ 2–8 nu-
cleotides 3′) of mature miRNA and 3′UTR of their tar-
get by Watson-Crick base-pairing is considered to be
the major determinant in blocking the target mRNA ei-
ther by translational repression or mRNA degradation
[43]. However other 3′- supplementary and 3′- compen-
satory binding sites in miRNA sequence also play a sig-
nificant role during interactions [24]. Although miRNA
binding sites are most common in 3′UTRs of mRNAs,
yet there are some reports of miRNA interaction within
the 5′UTR, mRNA coding region and intron-exon junc-
tions [44,45]. The detailed mechanisms underlying the
inhibition of protein synthesis by miRNAs are not well
understood, but literature suggests sequestration of mRNA
into P bodies from ribosomes, blockage of translational
initiation, translational repression or target deadenylation
coupled to transcript degradation [23,46]. However, it is
now believed that miRNA regulate gene expression in ma-
jority of cases by mRNA decay rather than translational
repression [47]. Epigenetic modifications and transcription
factors also play a decent role in the regulation of miRNA
function. Recent reports also depict the role of pseudo-
genes as miRNA sequestering sponges or decoys in the
regulation of miRNA function [48,49].
MicroRNAs in brain development and function
The brain is a complex organ, with various types of cells
(neurons and non-neurons) that form an intricate com-
munication network. Literature reveals that 70% of known
miRNAs are expressed in the brain [50]. Surprisingly, only
a handful of microRNAs are expressed in a brain specific
or brain-enriched manner [51]. Since these miRNAs are
dynamically regulated during brain development, have
Figure 1 miRNA biogenesis pathway and function: miRNAs are transcribed in the nucleus either from introns or exons of protein-coding
genes or introns of long non-coding RNAs into primary transcripts (pri-miRNAs). Pri-miRNAs are then processed in two steps in the nucleus and
cytoplasm, catalyzed by the RNase III type endonucleases Drosha and Dicer, in complexes with dsRNA-binding domain proteins, DGCR8 and TRBP
respectively. In the canonical pathway, Drosha-DGCR8 processes the transcript to a stem loop-hairpin precursor (pre-miRNA). Intron derived miRNAs,
called miRtrons, evade canonical pathway and processed by the spliceosome and the debranching enzyme into pre-miRNAs. Both canonical miRNAs
and miRtrons are exported to the cytoplasm via Exportin 5, where they are further processed by Dicer-TRBP or by Ago2 to yield 20-25-bp miRNA
duplexes. Dicer processing adds 5′ phosphate groups and two-nucleotide overhangs at the 3′ ends of the mature strands. The duplex produced by
either Dicer or Ago2 is loaded onto an Argonaute protein of RISC where one strand is selected to function as mature miRNA while the partner miRNA*
strand is preferentially degraded. The mature miRNA produced by these two mechanisms leads to translational repression or mRNA degradation.
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herein we provide a comprehensive list of the recent vali-
dated roles of brain-enriched and brain-specific micro-
RNAs along with their targets in brain in Tables 1 and 2.
The increasing variety of miRNAs being identified in the
brain suggests a sheer connection between the biogenesis,
dynamics of action and regulatory potential of miRNAs
and the complexity of the brain. Numerous studies on de-
pletion of the Dicer gene in the nervous system of animal
models further demonstrate that microRNAs play essential
roles in controlling neuronal proliferation, migration and
precursor fates [167-171] and serve important roles in de-
velopment and function in the brain [172,173]. Stark et al.
in their study, have illustrated the contribution of defects
in miRNA biogenesis to brain abnormalities in Dicer defi-
cient mice and mouse model of schizophrenia [174].
An expression profiling study by Sempere et al. showed a
group of 17 miRNAs were expressed in mouse and human
brain (miR-7, -9, -9*, -124a, -124b, -125a, -125b, -128, -
132, -135, -137, -139, -153, -149, -183, -190, -219). Allthese miRNAs have been found to regulate neuronal differ-
entiation, maturation, and/or survival in mouse and hu-
man. Conservation of these miRNAs between mouse and
human suggests that they may play a conserved role in the
establishment and/or maintenance of a cell or tissue type
of brain [52,55,106,175]. Specific expression of miR-9 and
miR-132 is restricted to hippocampus and medal frontal
gyrus [176] whereas miR-124 and miR-128 are unique for
neurons and miR-23, miR-26 and miR-29 are specifically
expressed in astrocytes [177]. In addition miR-195 displays
a moderate to low expression level in the mammalian em-
bryonic brain, with the highest level at the preadult brain
developmental stage [178].
Studies have further shown that miR-9 expression is
necessary for neurogenesis in cultured stem cells and
miR-132 plays a role in neurite extension and neurogen-
esis [52,179]. MiR-132 has also been linked to BDNF (a
member of the nerve growth factor family that is neces-
sary for survival of striatal neurons in the brain) and
MeCP2 (methyl-CpG DNA binding protein that plays an




miR-9* SOX2 Induces neuronal differentiation, affects both proliferation
and differentiation
[52-54]
miRNA-128 Reelin, DCX, SUZ12, neurofibromin 1, BMI1, RTK, EGFR,
PDGFRαUPF1, MLN51, NTRK3, WEE1, Bax, E2F3a, SNAP25
Synaptogenesis; reduces neuroblastoma cell motility and
invasiveness; suppressor of PRC activity; renders glioma
stemlike cells less radioresistant; suppressor of the colony
formation ability and invasiveness of pituitary tumor cells;
suppressor of growth and mediates differentiation;
regulates Nonsense-mediated decay; regulates apoptosis,
inhibits proliferation and self-renewal,
[55-68]
miR-7 KLF4, α-synuclein, Sepp1b, EGFR, IRS-2 Suppresses brain metastasis, control neurite outgrowth,
protects against oxidative stress, potential tumor
suppressor, decreases viability and invasiveness of
primary glioblastoma
[65,69-74]
miR-125 a-b NR2A, SMG1, SMAD4 regulates synaptic plasticity; regulates
Nonsense-mediated decay.
[52,75-77]
miR-23 laminB1,X-linked inhibitor of apoptosis (XIAP) regulates oligodendrocyte development and myelination,
regulates cerebral ischemia and neural specification
[78,79]
miR-132 PTBP2, AChE, FoxP2, Sirt1, MeCP2, ATA2, DPYSL3, STAT4;
p250RhoGAP, Mecp2, Ep300, Jarid1a, Btg2, Paip2a,
For more targets view [80]
Regulates progressive supranuclear palsy, regulator of the
brain-to-body resolution of inflammation, contribute to
neurodevelopmental and neuromorphological pathologies,
neuronal cell development, regulate synaptic plasticity,
neuronal maturation, regulates basal and activity-induced
neurite outgrowth, regulates recognition memory and
synaptic plasticity, regulates Circadian Clock.
[52,80-93]
miR-137 CDK6, MindBomb-1, CSMD1, C10orf26, CACNA1C, TCF4,
ZNF804A, neurofibromin 1, CSE1L, Cox-2, LSD1, MITF,
EZH2, KLF4, SPTLC1, For more targets view [94]
Inhibit proliferation of glioblastoma multiforme cells and
induce differentiation of brain tumor stem cells, neuronal
maturation, regulates differentiation of neural stem cells,
suppress growth and invasion of oligodendroglioma and
glioma cells,
[52,67,94-102]
miR-139 Mcl-1, C-X-C chemokine receptor type 4 (CXCR4),
FoxO1, CPG1, Bcl2
Suppressor of the proliferation and enhances drug induced
apoptosis, Reduced invasion and metastasis, Regulates
Transcriptional activity.
[52,88,103-105]
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feedback loop [81]. Interestingly, miR-124 when overex-
pressed in non-neuronal HeLa cells shifts the gene ex-
pression profile from an immature cervix cell into a
neuronal phenotype, suggesting that miR-124 downregu-
lates mRNAs directing cells into a non-neuronal pheno-
type [180]. Recently, it has been observed that MiR-124
targets REST, BTBP and Sox9, all proteins have been
known to antagonize the formation of neuronal cells
during development [106,113,114]. Similar to miR-124,
miRNA-128 is induced during brain development and in
differentiating neuronal cells; leading to repressed NMD
(Nonsense-mediated decay) and the consequent upregu-
lation of batteries of mRNAs encoding proteins import-
ant for neuron differentiation and function [56]. MiR-23
is implicated in neural specification while miR-26 is re-
quired during neuronal cell differentiation. Report by
Kole et al. showed that miR-29b is markedly induced
during neuronal maturation and functions as a inhibitor
of neuronal apoptosis [181]. Apart from development,
aberrant microRNA expression has been discovered inhuman CNS (central nervous system) diseases including
brain tumors in the past decade.
Dysfunction of microRNAs in brain tumors
Gliomas are the primary brain tumors that are made up
of glial cells which provide important structural support
for the nerve cells in the brain. Malignant gliomas are
the most common and lethal tumors arising in the central
nervous system and are classified by the World Health
Organization (WHO) into four different grades based on
malignancy (I, II, III, IV) [182,183]. Grade IV glioblastoma
multiforme (GBM) is the most common lethal primary
brain tumor in adults that is characterized by aggressive
vascular proliferation, invasiveness, stem cell-like behav-
iour and chemoresistance to new and traditional therapies
[183]. Accumulating evidences indicate the presence of
different miRNAs with pro-oncogenic and anti-oncogenic
properties in glioblastomas. Koshkin et al. recently ob-
served gradual increase in miR-21 and miR-23a levels in
all tumor grades and significant decrease of miR-7 and
miR-137 depending on the glioma grade [184]. Further,




miR-9 KCNMA1, cyclicAMP response element-binding protein (CREB),
neurofibromin 1 (NF1), Hes1, FoxP2, prelamin A
Promotes Neuronal differentiation, Inhibits
proliferation, Promotes migration, Control neural
stem cell differentiation
[65,87,106-112]
miR-124 a-b SNAI2, NR3C2, SOS1, CDK4, Usp14, inhibitory member of the
apoptosis-stimulating proteins of p53 family (iASPP), AMPA2
and AMPA3, SCP-1, PTBP1, Sox9, Ephrin-B1, JAG1, BAF53a,
CDK6, p38α mitogen-activated protein kinase, CEBPa, RhoG,
anachronism (ana), SNAI2, Lhx2, Ctdsp1, BACE1, NeuroD1
Promotes neuronal transcriptome/neurogenesis;
inhibit proliferation of glioblastoma multiforme
cells and induce differentiation of brain tumor stem
cells, regulation of renin-angiotensin-aldosterone
system, radiosensitize Glioblastoma multiforme
cells, promotes neuronal survival under ischemic
conditions, induce differentiation into neurons,
regulates the migration of glioma cells and the
self-renewal of GSCs, inhibits growth of
medulloblastoma xenograft tumors, regulates
neuroblast proliferation, alleviates cell death.
[53,65,95,113-134]
miR-134 Nanog, LRH1, Forkhead Box M1 (FOXM1), μ-opioid receptor
(MOR), DPD gene (DPYD), Xenopus LIM kinase 1 (Xlimk1), cMYC,
Pum2, Dcx and Chrdl-1, CREB, splicing factor SC35, Limk1
Controls dendritic spine development, control
synaptic protein synthesis and plasticity, inhibits
cell proliferation, invasion and migration capability
and promotes apoptosis, inhibits epithelial to
mesenchymal transition, guidance of nerve growth
cones, growth-promoting effect on dendritogenesis;
inducer of pluripotent stem cell differentiation;
stage-specific modulation of cortical development,
regulates memory, modify both alternative splicing
and cholinergic neurotransmission
[135-147]
miR-135 Focal Adhesion Kinase (FAK), EB1, NR3C2, Smad5, APC Decreased cell invasion and increased drug
sensitivity, regulation of immunity, regulation of
renin-angiotensin-aldosterone system, inhibit
differentiation of osteoprogenitors, regulates Wnt
signaling pathway.
[52,118,148-151]
miR-153 SNCA, BSN, PCLO, amyloid-β (Aβ) precursor protein (APP),
APLP2, alpha-synuclein, Bcl-2 and Mcl-1, SNAI1 and ZEB2
Promote neuronal differentiation, impairs
self-renewal ability and induces differentiation,
repress growth and induce apoptosis of GBM-stem
cells, decreases cell proliferation and increases
apoptosis in GBM cell line, regulates
epithelial-mesenchymal transition and tumor
metastasis, regulate gliomagenesis.
[52,152-159]
miR-219 EGFR, PLK2, Sox6, FoxJ3, PDGFRα, ZFP238,
ELOVL7, CaMKIIgamma
Inhibits the proliferation, anchorage independent
growth and migration of glioma cells, promote
oligodendrocyte differentiation and myelination,
modulates NMDA receptor-mediated neurobehavioral
dysfunction, maintenance of lipids and redox
homeostasis in mature Olligodendrocytes, regulates
circadian rhythms of expression.
[52,160-166]
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gliomas and confers a poor prognosis in glioma patients
[185]. MicroRNA-206 has been found to be a tumor sup-
pressor in human malignant cancers. Low miR-206 expres-
sion is associated with poor overall survival in patients with
malignant astrocytomas, hence it could become a valuable
marker of astrocytoma progression [186]. Apart from these,
several independent studies observed that the expressions
of miR-16, miR-503, miR-203, miR-34c-3p, miR-34c-5p,
miR-106a, Let-7a, miR-218, miR-223, miR-34a, miR-329,
miR-145, miR-124, miR-137, miR-138, miR-219-5p, miR-
495, miR-383, miR-200b, miR-134, miR-153, miR-195,
miR-143, miR-107, miR-326, miR-204 and miR-214 were
significantly reduced in high WHO grade glioma tissues
relative to low WHO grade glioma tissues and normal braintissues [115,135,152,160,187-208]. The expression of most
of these miRNAs decreases with increasing degrees of ma-
lignancy. The low expression of Let-7a was correlated with
poor prognosis of primary glioblastoma patients [192]. Fur-
ther, miR-708 and miR-17 ∼ 92 cluster were downregulated
in GBM tumor cell lines whereas three miR-17 ~ 92 cluster
miRNAs (miR-2, -19a and −20) were upregulated in human
medulloblastoma with aberrantly activated sonic hedgehog
(SHH) signaling pathway [209-211]. Another group by
Skalsky and Ciafre et al. in their cluster analysis further re-
vealed that miR-139, miR-95 and miR-873 were down-
regulated specifically in glioblastomas and miR-137 and
miR-181a/b were down-regulated in gliomas whereas miR-
7, miR-124 and miRNA-128 were down-regulated in both
[212,213]. Interestingly, miRNA-128 and miR-124 are not
Figure 2 Roles of miRNA-128 in different cellular processes:
The role of miRNA-128 in the different biological processes and
multistep events that lead to cancer are shown. The
experimentally validated target genes of miRNA-128 are depicted
along with the respective biological processes.
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including medulloblastomas and neuroblastomas [212,214].
Li et al. reported that decreased miR-146b-5p expression
was strongly correlated with chromosome 10q loss in gli-
omas, especially glioblastomas [215]. The significance of
the sequence of miRNA can be illustrated by the example
of miR-23 in brain. The expression of miRNA-23b was
gradually downregulated with the malignancy of glioma
whereas miR-23a was upregulated in malignant glioma tis-
sues [216,217]. Further, miR-328, miR-106b-5p, miR-155,
miR-650, miR-92b, miR-30a-5p, miR-10b, miR-372, miR-
183, miR-486 and miR-17 were found to be upregulated in
invading glioma cells in vivo and glioma tissues respectively
as revealed by miRNA expression profiling of microdis-
sected human tumor biopsy specimens [218-228]. MiR-650
expression can be used as a significant prognostic indicator
in glioma. MiR-19a, -19b and miR-9 have been found to be
overexpressed in glioma cell lines and astrocytic glioma tis-
sues, and their expression level is positively correlated with
tumor grades [107,229]. Several studies showed that miR-
21 and miR-10b are upregulated in glioblastomas and has
recently been shown to be a significant contributor for
tumor growth in vivo [230,231]. Wu et al. have recently
documented that overall patient survival for those with low
miR-21 expression was significantly longer than those
patients with high miR-21 expression [232]. Further,
miRNA-21, 221, 222, 181b, 181c, and 128a were found
to be significantly deregulated in GBM tissues by Slaby
et al. and Zhou et al. It was also observed that miRNA-
181b and 181c were the most down regulated miRNAs
in patients who responded to radiation therapy (RT) and
temozolomide (TMZ) and hence could serve as predictors
for RT/TMZ response. Several differentially expressed miR-
NAs such as miR-124, miR-21, -128, -181, -221 and −222
could serve as potential biomarkers in GBM in general
since they play common role in the etiology of malignant
brain tumors [233,234].
Role of pro-neural miRNA-128 in brain related disorders
MiRNA-128 is transcribed by two distinct genes, miRNA-
128-1 and miRNA-128-2 in two primary transcripts, which
are processed into an identical mature miRNA sequence.
MiRNA-128-1 and miRNA-128-2 are both present in the
intronic regions of two genes on two different chromo-
somes. MiRNA-128-1 is embedded in the R3HDM1 (R3H
domain containing 1) gene on chromosome 2q21.3 and
miRNA-128-2 is in the ARPP21 (cyclic AMP-regulated
phosphoprotein, 21 kDa) on chromosome 3p22.3 [57]. Evi-
dences in the literature reveal that miRNA-128 has tissue
specific and developmental specific expression patterns.
Apart from brain, miRNA-128 has also been found in the
skeletal muscle and thymus and is highly expressed during
neuronal differentiation. Down regulation of miRNA-128
has been reported in several brain cancers for example-glioblastoma [213] and medulloblastoma [235]. Allelic loss
in chromosome 3p, where miRNA-128-2 is present, has
also been associated with the most aggressive forms of
neuroblastoma [213].
Cui et al. demonstrated that the down-regulation of
miRNA-128 inversely correlates with tumor grade. They
also observed that the decrease of miRNA-128 is coupled
with significant increase in the expression of Bmi-1, the
transcription factor E2F-3a and angiopoietin-related growth
factor protein 5 (ARP5; ANGPTL6). Increased expression
of these factors may explain the undifferentiated, self-
renewing state of brain cells and de-regulated cell-cycle
signaling pathways that support cellular proliferation
in glioma and GBM [236]. Zhang et al. in his study
showed that brain-enriched miRNA-128 was also down
regulated in glioma tissues and cell-lines and overex-
pression of miRNA-128 inhibited cellular proliferation
through negatively regulating E2F3a, which is highly
expressed in glioma and important for cell cycle pro-
gression (Figure 2) [58]. Papagiannakopoulos et al. re-
cently showed that miRNA-128 represses growth and
enhances neuronal differentiation of glioma-initiating
neural stem cells (giNSCs) by downregulating onco-
genic receptor tyrosine kinases (RTKs), epithelial growth
factor receptor (EGFR) and platelet-derived growth factor
receptor-α (PDGFRα) (Figure 2) [59]. In an independent
study, Godlewski et al., reported that overexpression of
miRNA-128 reduces glioma cell proliferation by downreg-
ulating Bmi-1 (B lymphoma mouse Moloney leukemia
virus insertion region 1), decrease in histone methylation
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of p21CIP1 levels [60]. As Bmi-1 is also known to pro-
mote the stem cell renewal, a process that is important in
glioma, hence miRNA-128 may be used against the “stem
cell-like” characteristics of glioma cells [237]. These data
suggest that miRNA-128 may suppress cancer pathogenesis
by inducing differentiation out of a stem cell-like state. Roth
et al. recently reported upregulation of miRNA-128 in the
blood samples of glioblastoma patients compared to healthy
controls and speculated that this miRNA fingerprint may
be used as suitable biomarker for glioblastoma [238].
Besides these, levels of miRNA-128 have been reported
to be deregulated in autism, prion-induced neurode-
generation, Huntington disease, Parkinson disease and
Alzheimer disease [239-242]. Several evidences in the lite-
rature show that under different biological conditions,
expression patterns of miRNA-128 varies i.e. in some in-
stances, it is up regulated whereas in some, it is down
regulated (Table 3). Furthermore, Eletto et al. in his study
showed that miRNA-128a inhibits expression of theTable 3 The pathological conditions in which miRNA-128 is im
to both hsa-miRNA-128a and b)
miRNA Disease
hsa-miRNA-128a Acute lymphoblastic leukemia (ALL)
hsa-miRNA-128a Acute myeloid leukemia (AML)
hsa-miRNA-128a Alzheimer’s disease
hsa-miRNA-128a Autism spectrum disorder (ASD)
hsa-miRNA-128a Glioblastoma
hsa-miRNA-128a Glioblastoma multiforme (GBM)
hsa-miRNA-128a Malignant melanoma




hsa-miRNA-128b Acute lymphoblastic leukemia (ALL)







hsa-miRNA-128b Hepatocellular carcinoma (HCC)




hsa-miRNA-128 Huntington’s diseasepre-synaptic protein SNAP25 by binding to its 3′UTR
(Figure 2). They observed Tat mediated deregulation of
miRNA-128, in primary cortical neurons during the
infection of neurons by HIV-1. However, the role of
miRNA-128a in regulating synaptic activity in normal and
in neurodegenerative disorders including HIV-1 Encephal-
opathy (HIVE) needs to be determined [61].
Expression of pro-neural miRNA-128 in cancers other
than brain
Cancer occurs due to accumulation of several genomic
alterations and is characterized by unrestricted prolifera-
tion, invasion, and metastasis. miRNAs normally negatively
regulate their transcript targets and recent evidence indi-
cates that miRNAs may function as tumor suppressors (by
binding to oncogenes and suppressing them) or oncogenes
(by binding to tumor suppressor genes and suppressing
them) and alterations in miRNA expression may play a crit-
ical role in the cancer initiation and progression [255,256].
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dant miRNome data are currently available for various
cancers. MiRNA expression can be correlated with can-
cer type, stage, and other clinical variables which may
be useful for the classification, diagnosis, or prognosis
of some human malignancies [257]. With respect to
miRNA-128, it is known that miRNA-128 may act as a
tumor-suppressor. Kotani et al. in his study reported
down regulation of miRNA-128 in MLL-AF4 Acute
Lymphocytic Leukemia and Khan et al. revealed down
regulation of miRNA-128 in invasive prostate cancer
cells as compared to benign prostate epithelial cell lines,
where its levels are elevated [254,258]. In addition,
miRNA-128 was significantly reduced in chemoresistant
breast tumor-initiating cells (BT-ICs) enriched from breast
cancer cell lines and primary breast tumors (P < 0.01), ac-
companied by an overexpression of Bmi-1 and ABCC5,
which were identified as targets of miRNA-128 [259]. In
contrast to these studies, strong induction of miRNA-128
has been observed in endometrial cancer [260] as well as
in acute lymphoblastic leukemia (ALL) [244]. Up regula-
tion of miRNA-128 not only suppressed the colony forma-
tion ability and invasiveness of pituitary tumor cells but
also suppressed pituitary GH3 tumor growth in xenografts
via, Bmi-1. MiRNA-128 found to regulate its direct target
Bmi-1 and PTEN-AKT pathway in pituitary tumors [62].
Allelic loss in chromosome 3p (where miRNA-128-2 is
present) has been shown to be associated with the most ag-
gressive form of lung carcinogenesis. Furthermore, it was
observed that loss of heterozygosity (LOH) of MicroRNA-
128b in tumor samples correlated significantly with clinical
response and survival following Gefitinib via EGFR [249].
Although the increase/decrease of miRNA-128 has been
reported in a number of the studies related to cancer but it
is not known whether it is a cause or effect of the disease.
Pro-neural miRNA-128 as regulator of apoptosis
Alterations in susceptibility to apoptosis is a key factor
for the survival of a malignant cell [261] and it enhances
resistance to conventional anticancer therapies [262]. As
the altered expression of pro-neural miRNA-128 was found
in several cancers, numerous studies were undertaken to
delineate the mechanism for the inhibition of cell prolif-
eration and induction of apoptosis by miRNA-128. Sean
Lawler’s laboratory demonstrated that ectopic expres-
sion of miRNA-128 in human glioma neurosphere cul-
tures (having stem-like properties) led to reduction in
glioma neurosphere number and volume by down regulat-
ing Bmi-1 (Figure 2) [60]. In addition to this, several inde-
pendent studies have illustrated the anti-proliferative role
of miRNA-128 in glioma cells and glioblastoma cell lines
[58,236]. Infact, ginsenoside Rh2, a triterpene saponin has
also been found to inhibit glioma cell proliferation by up-
regulating microRNA-128 [263]. Further, over expressionof miRNA-128 leads to an alteration in the expression
of genes implicated in cytoskeletal organization (via
truncated isoform of NTRK3) as well as genes involved
in apoptosis, cell survival and proliferation, including the
anti-apoptotic factor BCL2 in SH-SY5Y neuroblastoma
cells [63]. In our laboratory also, we recently observed that
miRNA-128 overexpression induced apoptosis by down
regulation of Bax and up regulation of p53 and Bak [57].
Furthermore, transcriptome analysis of miRNA-128 overex-
pressed cells revealed that miRNA-128 inhibits SIRT1
expression directly through a miRNA-128 binding site
within the 3′UTR of SIRT1 (Figure 2). Finally, we found
that miRNA-128 induces apoptosis in wild type (WT)
p53 as well as in mutant p53-expressing cells in a p53-
dependent and -independent manner via induction of
PUMA in MCF7, MDA-MB-231, HCT116 p53 +/+ and
HCT116 p53 −/− cells respectively [264]. In our study,
we also demonstrated that miRNA-128 augments the an-
titumor effects of compounds (Etoposide and Cisplatin).
Contrary to our findings, Yolanda’s group has shown that
ectopic expression of miRNA-128 downregulated genes
that induce apoptosis and upregulated genes implicated in
cell survival [63]. In an another recent study, miRNA-128
was found to target Bax in breast cancer cell line MDA-
MB-231 and downregulation of miRNA-128 sensitised
MDA-MB-231 cells to chemodrugs [265]. Furthermore,
Donzelli et al. observed that miRNA-128-2 expression in
lung cancer cells inhibits apoptosis and confers increased
resistance to cisplatin, doxorubicin and 5-Fluorouracyl
treatment via E2F5 (Figure 2) [266]. Based on the above
information, we can say that depending upon the cell
type; miRNA-128 can have anti-apoptotic as well as
pro-apoptotic functions. It seems that miRNA-128 can
be targeted to facilitate cancer cell death and/or inhibit
cancer cell growth; however, this aspect warrants fur-
ther investigation.
Role of miRNA-128 in cell motility, angiogenesis
and senescence
Ability to migrate and eventually disseminate to distal sites
is one of the key characteristic of tumor cells, which is also
responsible for the relative aggressiveness of the tumor.
Data from several independent studies showed that over-
expression of miRNA-128 inhibits cell motility and inva-
siveness. Evangelisti et al. proved that overexpression of
miRNA-128 reduces neuroblastoma cell motility and inva-
siveness by targeting Reelin and DCX (Figure 2) [55]. DCX
is a microtubule-associated protein required for neuroblas-
tic migration during cerebral cortex development [267]
while Reelin is a high-molecular-weight secreted glycopro-
tein, which is thought to play its role as a guide for migra-
tory neurons [268]. Messi et al. described DCX as a
marker of SK-N-SH neuroblastoma cells that show high
motility and invasiveness [269]. DCX expression is also
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as GBM and neuroblastoma. Reelin has been shown to
be a positive marker for prostate carcinoma aggressive-
ness [270] and is overexpressed in retinoblastoma and
esophageal carcinoma and its expression is directly cor-
related with tumor aggressiveness [271,272]. Khan et al.
investigated the proteomic alterations in a cohort of 15
prostate-derived tissues from adjacent benign prostate
(Benign), clinically localized prostate cancer (PCA) and
metastatic disease from distant sites (Mets). By coupling
multidimensional protein fractionation and quantitative
mass spectrometry with bioinformatics-based enrichment
analysis, they demonstrated the involvement of miRNA-
128 in the stages of prostate cancer progression. They have
shown using qRT-PCR that miRNA-128 levels were re-
duced in invasive prostate cancer cells as compared to be-
nign prostate epithelial cell lines. Further, over expression
of miRNA-128 attenuated invasion in prostate cancer cells
while its knockdown induced invasion in benign prostate
epithelial cells as revealed by matrigel invasion assay [258].
These findings suggest that miRNA-128 reduces cell mo-
tility and invasiveness of tumor cells and thus prevents
angiogenesis. In an independent study, Shi et al. observed
that miRNA-128 overexpression inhibited tumorigenesis
and angiogenesis through targeting p70S6K1 and sup-
pressing downstream molecules of p70S6K1 such as HIF-1
and VEGF [273]. Their study identified a link between
miRNA-128 and p70S6K1 axis, which plays a vital role in
glioma angiogenesis (Figure 2).
Over expression of Bmi-1 oncogene has been found to
promote NSC self-renewal by repressing the p16Ink4a
and p19Arf senescence pathways [274]. As miRNA-128
directly targets Bmi-1 oncogene, the role of miRNA-128
in senescence is also evident. Observation by Venkatra-
man’s group of increased methylation of histone 3 lysine
9 (H3K9me2) (a mark of repressed gene expression me-
diated by the Bmi-1 polycomb repressor complex) after
overexpression of miRNA-128 further confirms the role
of miRNA-128 in promoting cellular senescence. They
also observed that overexpression of miRNA-128a in
medulloblastoma alters the intracellular redox state of
the tumor cells. In our study also, over expression of
miRNA-128 in HEK293T cells led to an increase in re-
active oxygen species [57]. This is quite interesting for
therapeutic scenario where miRNA-128 can be used as
therapeutic modality for treating cancer, as cancer stem
cells are more resistant to therapy due to a lower overall
redox state, where it can induce ROS [235].
Insights into regulation of cholesterol metabolism
by miRNA-128: a new key player in cholesterol
related disorders
Aberrant regulation of cholesterol homeostasis is associ-
ated with obesity as well as multiple types of cancer. Theregulation of cholesterol homeostasis pathways is com-
plex with transcriptional regulation by sterol-regulatory
element-binding protein (SREBP) and liver X receptor/
retinoid X receptor (RXR) transcription factors but poorly
understood at the post-transcriptional levels [275,276].
While investigating the mechanism of miRNA-128 induced
apoptosis, we observed that besides regulating the genes of
apoptosis, miRNA-128 also regulates cholesterol metabol-
ism and fatty acid biosynthesis pathways. In our study, we
discovered that miRNA-128 up-regulated cholesterol syn-
thesis genes and down regulated fatty acid biosynthesis
genes. miRNA-128 further affected cholesterol efflux path-
way by direct targeting ABCA1, ABCG1 and RXRα
(Figure 2). We provided the first evidence of miRNA-
128-2 to be a new regulator of cholesterol homeostasis
[277]. Our invitro results present a novel opportunity
to investigate microRNA related interactions invivo and
their role in cholesterol regulation. We believe validation
using invivo model should not only provide novel insights
into understanding of cholesterol regulation by miRNAs
but should also help us to combat a variety of cholesterol
related pathologies.
Biological relevance of miRNA-128 as revealed by
bioinformatic analysis
The overall cellular functions and pathways affected by
this miRNA remains still undiscovered due to lack of high
throughput target validation methods. To reveal biological
significance of miRNA-128, a list of predicted targets of
miRNA-128 was made using the miRNA target prediction
software, TargetScan 5 program (Table 4) [278]. From this
list, we discovered that 90 targets of miRNA-128 were
conserved among 9 species (Human, Mouse, Chimpanzee,
Rhesus, Cow, Chicken, Frog, Rat, Opossum); thereby indi-
cating possible mechanistically conserved functions of this
miRNA (Figure 3). To evaluate the specific pathways or
processes that are targeted by miRNA-128, we used the
list of these ninety conserved targets to find enriched
pathways by the PANTHER and GeneCodis [279,280]
analysis. Insulin/IGF pathway-mitogen activated protein
kinase kinase/MAP kinase cascade, TGF-beta signaling
pathway, Angiogenesis, Insulin/IGF pathway-protein kin-
ase B signaling cascade, PI3 kinase pathway, Wnt signaling
pathway were found to be the most enriched biological
pathways as revealed by the PANTHER analysis (Figure 4).
Interestingly, we observed that the Insulin signaling path-
way and chemokine signaling pathway were the enriched
categories (p-value < 0.05) in both PANTHER and Gene-
Codis analysis. Till now, only one study by Motohashi et al.
describes about the regulation of Insulin signaling pathways
by miRNA-128a via the regulation of INSR (insulin recep-
tor), IRS1 (insulin receptor substrate 1) and PIK3R1 (phos-
phatidylinositol 3-kinases regulatory 1) [281]. There are a
few reports which have talked about the involvement of
Table 4 List of ninety conserved targets of miRNA-128
among nine species
C1orf144 FOXP2 RELN ARFGEF1
AFF4 CORO1C ENAH C5orf41
EYA4 WSB1 hCG_1757335 JMJD1C
PLK2 PLAG1 IRS1 NDUFS4
ONECUT2 NRP2 RNF38 UPF1
RYBP HAPLN1 PDE7B SPRY2
SOCS6 CDH11 MAPK14 ELL2
UBR5 ZHX1 UBE2N DLL4
LBH STK39 MED13 MLL3
C6orf60 PDS5B GRIA3 MEIS2
SYT1 SEMA6A RAP1B SPOPL
BAZ2B ZNF827 UBE2W RAPGEF2
APBA2 FLRT3 ZNF618 MARCKS
ISL1 KLF4 TMEFF1 ARID2
UNC13C DNAJC13 tcag7.1228 ZFHX4
FRYL SERTAD2 AFF3 CPEB3
C5orf13 INSM1 CITED2 TMEM189-UBE2V1
WNK1 SATB2 NARG1 UBE2V1
FBXO33 HOXA10 TSC1 CPEB4
TNPO1 OTX2 MED14 EN2
ABL2 APPBP2 FUBP3 PDE3B
PPP1CC PELI2 NIPBL MAN2A1
ARID1B ATP2B1
Figure 3 Strategy for filtering common genes among nine species: Tota
program for nine species (Human, Mouse, Chimpanzee, Rhesus, Cow, C
where the union of all genes from the mentioned species were represented a
row had species names in them (column head). For every gene, 1 was written
otherwise. This way, a matrix of 1 and zeroes was populated for every gene w
sum across the row was taken to count the number of species in which a pa
all nine species. This led to a list of ninety genes which we called high confid
specifies ninety common targets whereas red specifies the absence of a parti
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way [60]. The reports which have revealed the associ-
ation between miRNA-128 and angiogenesis, have been
described by us in the above section. However, regulation
of Wnt signaling and chemokine signaling pathways by
miRNA-128 needs further validation. Surprisingly, meta-
bolic process came out to be the highest rated biological
process with maximum number of genes during PAN-
THER Analysis (Figure 5). Our recent work on the regula-
tion of cholesterol metabolism by miRNA-128 point
towards a possible link between miRNA-128 and metabolic
processes which is just beginning to be revealed and cer-
tainly merits further studies. Such discoveries not only pro-
vide new insights into mode of action of miRNA-128, but
also raise hopes for translating miRNA-128 for therapy.
Future directions/conclusions
MiRNA-128 is encoded by two distinct genes, viz.,
R3HDM1 and ARPP21. Interestingly, insilico analysis of
transcription factor binding sites of these two genes re-
veals almost similar pattern of transcription factors
(unpublised data). This suggests that these two genes
may presumably resulted from a gene duplication event.
Until now, neither transcription factors binding proteins
of hsa-miRNA-128 gene nor epigenetic factors, have
been identified that interact with the regulatory region
of this miRNA. However, Monteys et al. have recently
suggested dual regulation of miRNA-128-2 by both in-
tronic (pol III) and host gene (Pol II) promoters in acutel targets of miRNA-128 have been extracted using TargetScan 5
hicken, Frog, Rat, Opossum). Data was arranged in a tabular format
s first column in each row (row head). The subsequent columns in first
under the species where it was found to be present and zero
here 1 means presence and zero means absence. In the last column,
rticular gene was present. We chose only those genes with presence in
ence set and were conserved among these species. The total green area
cular target in a particular species out of nine species.
Figure 4 Biological relevance of miRNA-128 as revealed by bioinformatic analysis: The biological pathways affected by miRNA-128
were revealed by the PANTHER and Gene Codis analysis using the list of common ninet y targets as input. Insulin signaling pathway and
chemokine signaling pathway were the enriched categories in both PANTHER and GeneCodis analysis (p-value < 0.05).
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http://www.molecular-cancer.com/content/13/1/33lymphoblastic leukemia [283]. The fact that miRNA-128
plays multiple roles - a pro-apoptotic molecule, a anti-
apoptotic molecule as well as a regulator of cholesterol
homeostasis, raise the possibility of exploiting miRNA-
128 for therapeutic intervention and development ofFigure 5 GO biological processes by PANTHER analysis: The highest r
to be metabolic process with maximum number of genes during PANnovel therapies. Further, therapeutic modalities either
using replacement strategy by miRNA-128 mimetics (for
upregulation of miRNA-128) or using antisense miRNA
oligonucleotides (AMOs or antagomirs), LNAs (Locked
nucleic Acid) (for downregulation) may now be pursuedated biological process being affected by miRNA-128 came out
THER analysis.
Adlakha and Saini Molecular Cancer 2014, 13:33 Page 12 of 18
http://www.molecular-cancer.com/content/13/1/33in an effort to target a particular disease. We believe that
there are several fundamental questions that still need to
be answered and are open for investigation which will
help in the development of miRNA-128 as therapeutics.
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